Clinical Trial Detail

NCT ID NCT01396499
Title Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

leukemia

Therapies

Buparlisib

Age Groups: adult

No variant requirements are available.